Minimally important differences and risk levels for the Composite Asthma Severity Index

Rebecca Z. Krouse; Christine A. Sorkness; Jeremy J. Wildfire; Agustin Calatroni; Rebecca Gruchalla; Gurjit K.Khurana Hershey; Meyer Kattan; Andrew H. Liu; Melanie Makhija; Stephen J. Teach; Joseph B. West; Robert A. Wood; Edward M. Zoratti; Peter J. Gergen

doi:10.1016/j.jaci.2016.08.041

Minimally important differences and risk levels for the Composite Asthma Severity Index

Rebecca Z. Krouse, Christine A. Sorkness, Jeremy J. Wildfire, Agustin Calatroni, Rebecca Gruchalla, Gurjit K.Khurana Hershey, Meyer Kattan, Andrew H. Liu, Melanie Makhija, Stephen J. Teach, Joseph B. West, Robert A. Wood, Edward M. Zoratti, Peter J. Gergen

Pediatrics

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Original language	English (US)
Pages (from-to)	1052-1055
Number of pages	4
Journal	Journal of Allergy and Clinical Immunology
Volume	139
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2016.08.041
State	Published - Mar 2017

Funding

This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (contract nos. HHSN272200900052C, HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources, and National Center for Advancing Translational Sciences, NIH (grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Glaxo SmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2016.08.041

Cite this

Krouse, R. Z., Sorkness, C. A., Wildfire, J. J., Calatroni, A., Gruchalla, R., Hershey, G. K. K., Kattan, M., Liu, A. H., Makhija, M., Teach, S. J., West, J. B., Wood, R. A., Zoratti, E. M., & Gergen, P. J. (2017). Minimally important differences and risk levels for the Composite Asthma Severity Index. Journal of Allergy and Clinical Immunology, 139(3), 1052-1055. https://doi.org/10.1016/j.jaci.2016.08.041

@article{2087f83e1d9b4c2bbb328a2f2c720205,

title = "Minimally important differences and risk levels for the Composite Asthma Severity Index",

author = "Krouse, {Rebecca Z.} and Sorkness, {Christine A.} and Wildfire, {Jeremy J.} and Agustin Calatroni and Rebecca Gruchalla and Hershey, {Gurjit K.Khurana} and Meyer Kattan and Liu, {Andrew H.} and Melanie Makhija and Teach, {Stephen J.} and West, {Joseph B.} and Wood, {Robert A.} and Zoratti, {Edward M.} and Gergen, {Peter J.}",

note = "Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (contract nos. HHSN272200900052C, HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources, and National Center for Advancing Translational Sciences, NIH (grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Glaxo SmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.",

year = "2017",

month = mar,

doi = "10.1016/j.jaci.2016.08.041",

language = "English (US)",

volume = "139",

pages = "1052--1055",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

Krouse, RZ, Sorkness, CA, Wildfire, JJ, Calatroni, A, Gruchalla, R, Hershey, GKK, Kattan, M, Liu, AH, Makhija, M, Teach, SJ, West, JB, Wood, RA, Zoratti, EM & Gergen, PJ 2017, 'Minimally important differences and risk levels for the Composite Asthma Severity Index', Journal of Allergy and Clinical Immunology, vol. 139, no. 3, pp. 1052-1055. https://doi.org/10.1016/j.jaci.2016.08.041

TY - JOUR

T1 - Minimally important differences and risk levels for the Composite Asthma Severity Index

AU - Krouse, Rebecca Z.

AU - Sorkness, Christine A.

AU - Wildfire, Jeremy J.

AU - Calatroni, Agustin

AU - Gruchalla, Rebecca

AU - Hershey, Gurjit K.Khurana

AU - Kattan, Meyer

AU - Liu, Andrew H.

AU - Makhija, Melanie

AU - Teach, Stephen J.

AU - West, Joseph B.

AU - Wood, Robert A.

AU - Zoratti, Edward M.

AU - Gergen, Peter J.

N1 - Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (contract nos. HHSN272200900052C, HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources, and National Center for Advancing Translational Sciences, NIH (grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Glaxo SmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.

PY - 2017/3

Y1 - 2017/3

UR - http://www.scopus.com/inward/record.url?scp=85006726016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006726016&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2016.08.041

DO - 10.1016/j.jaci.2016.08.041

M3 - Article

C2 - 27744028

AN - SCOPUS:85006726016

SN - 0091-6749

VL - 139

SP - 1052

EP - 1055

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 3

ER -

Minimally important differences and risk levels for the Composite Asthma Severity Index

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this